



# Humanized Anti-Human IL-6R monoclonal antibody (Satralizumab), clone Satralizumab (DMABB-JX322)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Isotype</b>	IgG2
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	Human
<b>Clone</b>	Satralizumab
<b>Purification</b>	Affinity purified
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	Functional Assays Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
<b>Format</b>	Liquid
<b>Concentration</b>	Lot specific
<b>Size</b>	1 mg
<b>Buffer</b>	Supplied as a 0.22 µm filtered solution in PBS, pH 7.4
<b>Preservative</b>	None
<b>Storage</b>	Store at -20 °C or below for long term. Avoid freeze/thaw cycles.

## BACKGROUND

### Introduction

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions in the optic nerve, spinal cord, brainstem, and cerebrum.

---